STRATEC Biomedical shares rise on strong Q2 results
German diagnostics firm posts better-than-expected revenue and profit, lifting shares 8% in early trade.
STRATEC Biomedical shares climbed 8% in early Frankfurt trading on Tuesday after the German diagnostics equipment maker reported second-quarter results that exceeded market expectations.
The company posted revenue of €128.4 million for the three months ended June 30, up 11% from the same period last year and above the €120 million consensus estimate compiled by Refinitiv. Adjusted earnings before interest and taxes (EBIT) rose 16% year-over-year to €34.2 million, also surpassing forecasts.
STRATEC attributed the growth to strong demand for its automated laboratory systems and consumables, particularly in Europe and the Americas. The company noted that its order backlog remained robust at €220 million, providing visibility into future revenue streams.
Analysts at Berenberg maintained a buy rating on the stock, citing the company’s resilient performance amid broader economic uncertainty. The brokerage raised its price target to €110 from €100, reflecting a 20% upside from current levels.
STRATEC Biomedical’s shares, which have gained 15% year-to-date, were trading at €92.50 in mid-morning deals, up from Monday’s close of €85.60.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
